Sponsorship Statement: This continuing medical education activity is sponsored by 
.
Support Statement: This activity is supported by an educational grant from 
.
Target Audience: The intended audience for this activity is internists and other healthcare professionals involved in the treatment of patients with type 2 diabetes mellitus (T2DM).
Learning Objectives: Upon successful completion of this activity, participants will be able to:
- Explain the potential role of glucagon-like peptide-1 (GLP-1)-based therapies in reducing
cardiometabolic risk.
- Incorporate evidence-based data into practice on the use of GLP-1 agonists in combination with insulin glargine to effectively treat T2DM.
- Assess longer acting GLP-1 agonists for their ability to achieve hemoglobin A1c (HbA1C) targets and minimize adverse events that may affect adherence to therapy.
Course Chair:
Frank Lavernia, MD
Founder and Medical Director
North Broward Diabetes Center
Deerfield Beach, FL
Faculty:
Jack L. Leahy, MD
Professor of Medicine
Chief, Division of Endocrinology, Diabetes and Metabolism
University of Vermont
Burlington, VT
R. Daniel Pollom, MD
Medical Director
Diabetes Care Center
Community Health Network
Indianapolis, IN
Carol H. Wysham, MD
Clinical Assistant Professor of Medicine
University of Washington School of Medicine
Section Head, Endocrinology
Rockwood Clinic
Spokane, WA
External Reviewer:
Mark Schutta, MD
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, July 19, 2012 to July 18, 2013.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch and listen to the presentations, complete the posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Frank Lavernia, MD
Consulting Fees – Sanofi
Fees for Non-CME Services Received Directly from Commercial Interest – Abbott Pharmaceuticals and Novo Nordisk
Jack L. Leahy, MD
Consulting Fees – Novo Nordisk and Sanofi
Fees for Non-CME Services Received Directly from Commercial Interest – Johnson & Johnson, Merck and Takeda
Contracted Research – Takeda
R. Daniel Pollom, MD
Consulting Fees – Lilly, Merck and Novo Nordisk
Fees for Non-CME Services Received Directly from Commercial Interest – Lilly, Merck and Novo Nordisk
Carol H. Wysham, MD
Consulting Fees – Amylin, Johnson & Johnson and Novo Nordisk
Fees for Non-CME Services Received Directly from Commercial Interest – Amylin, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk and Sanofi
Contracted Research – Amylin, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk and Sanofi
External Reviewer reports the following relationship(s):
Mark Schutta, MD
Salary – Spouse is a director at Merck
Ownership Interest – Spouse owns stock options at Merck
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2012 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.